AbbVie announced acquisition of Capstan Therapeutics, a Leaps portfolio company focused on precise in vivo cell engineering for immunology.
JUN 30, 2025
Portfolio company Capstan Therapeutics was acquired by AbbVie in June 2025.
JUN 2025
Capstan Therapeutics is focused on in vivo engineering of cells through targeted lipid nanoparticles, aiming to address complex health issues and enhance people's lives
Capstan Therapeutics is focused on in vivo engineering of cells through targeted lipid nanoparticles, aiming to address complex health issues and enhance people's lives.